Novel Insights into the Impact of the SUMOylation Pathway in Hematological Malignancies (Review)

Overview

Journal Int J Oncol

Specialty Oncology

Date 2021 Aug 9

PMID 34368858

Citations 5

Authors

Ling Wang

Jinjun Qian

Ye Yang

Chunyan Gu

Affiliations

Soon will be listed here.

Abstract

The small ubiquitin‑like modifier (SUMO) system serves an important role in the regulation of protein stability and function. SUMOylation sustains the homeostatic equilibrium of protein function in normal tissues and numerous types of tumor. Accumulating evidence has revealed that SUMO enzymes participate in carcinogenesis via a series of complex cellular or extracellular processes. The present review outlines the physiological characteristics of the SUMOylation pathway and provides examples of SUMOylation participation in different cancer types, including in hematological malignancies (leukemia, lymphoma and myeloma). It has been indicated that the SUMO pathway may influence chromosomal instability, cell cycle progression, apoptosis and chemical drug resistance. The present review also discussed the possible relationship between SUMOylation and carcinogenic mechanisms, and evaluated their potential as biomarkers and therapeutic targets in the diagnosis and treatment of hematological malignancies. Developing and investigating inhibitors of SUMO conjugation in the future may offer promising potential as novel therapeutic strategies.

Citing Articles

Diagnostic and Therapeutic Implications of the SUMOylation Pathway in Acute Myeloid Leukemia.

Chatzikalil E, Arvanitakis K, Filippatos F, Diamantopoulos P, Koufakis T, Solomou E Cancers (Basel). 2025; 17(4).

PMID: 40002226 PMC: 11853134. DOI: 10.3390/cancers17040631.

Exploring the contribution of Zfp521/ZNF521 on primary hematopoietic stem/progenitor cells and leukemia progression.

Chiarella E Cell Tissue Res. 2024; 398(3):161-173.

PMID: 39436449 PMC: 11614986. DOI: 10.1007/s00441-024-03926-2.

Oxygen-regulated post-translation modifications as master signalling pathway in cells.

Batie M, Fasanya T, Kenneth N, Rocha S EMBO Rep. 2023; 24(12):e57849.

PMID: 37877678 PMC: 10702833. DOI: 10.15252/embr.202357849.

Host SUMOylation Pathway Negatively Regulates Protective Immune Responses and Promotes Survival.

Singhal J, Madan E, Chaurasiya A, Srivastava P, Singh N, Kaushik S Front Cell Infect Microbiol. 2022; 12:878136.

PMID: 35734580 PMC: 9207379. DOI: 10.3389/fcimb.2022.878136.

Identification of a prognostic signature based on copy number variations (CNVs) and CNV-modulated gene expression in acute myeloid leukemia.

Niu C, Wu D, Li A, Qin K, Hu D, Wang E Am J Transl Res. 2022; 13(12):13683-13696.

PMID: 35035707 PMC: 8748127.

References

Li Y, Wang H, Yang X, Geng H, Gong G, Kim H . Gene M55V Polymorphism and Type 2 Diabetes Mellitus: A Meta-analysis Including 6,823 Subjects. Front Endocrinol (Lausanne). 2017; 8:303. PMC: 5673665. DOI: 10.3389/fendo.2017.00303. View

Dawlaty M, Malureanu L, Jeganathan K, Kao E, Sustmann C, Tahk S . Resolution of sister centromeres requires RanBP2-mediated SUMOylation of topoisomerase IIalpha. Cell. 2008; 133(1):103-15. PMC: 2693193. DOI: 10.1016/j.cell.2008.01.045. View

Ohta S, Bukowski-Wills J, Sanchez-Pulido L, de Lima Alves F, Wood L, Chen Z . The protein composition of mitotic chromosomes determined using multiclassifier combinatorial proteomics. Cell. 2010; 142(5):810-21. PMC: 2982257. DOI: 10.1016/j.cell.2010.07.047. View

Verdaasdonk J, Bloom K . Centromeres: unique chromatin structures that drive chromosome segregation. Nat Rev Mol Cell Biol. 2011; 12(5):320-32. PMC: 3288958. DOI: 10.1038/nrm3107. View

Carter S, Bischof O, Dejean A, Vousden K . C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol. 2007; 9(4):428-35. DOI: 10.1038/ncb1562. View

Chang C, Naik M, Huang Y, Jeng J, Liao P, Kuo H . Structural and functional roles of Daxx SIM phosphorylation in SUMO paralog-selective binding and apoptosis modulation. Mol Cell. 2011; 42(1):62-74. DOI: 10.1016/j.molcel.2011.02.022. View

Brackett C, Blagg B . Current Status of SUMOylation Inhibitors. Curr Med Chem. 2020; 28(20):3892-3912. PMC: 8483067. DOI: 10.2174/0929867327666200810135039. View

Qiao Z, Wang W, Wang L, Wen D, Zhao Y, Wang Q . Design, synthesis, and biological evaluation of benzodiazepine-based SUMO-specific protease 1 inhibitors. Bioorg Med Chem Lett. 2011; 21(21):6389-92. DOI: 10.1016/j.bmcl.2011.08.101. View

Kumar A, Ito A, Hirohama M, Yoshida M, Zhang K . Identification of sumoylation activating enzyme 1 inhibitors by structure-based virtual screening. J Chem Inf Model. 2013; 53(4):809-20. DOI: 10.1021/ci300618e. View

10.

Boggio R, Colombo R, Hay R, Draetta G, Chiocca S . A mechanism for inhibiting the SUMO pathway. Mol Cell. 2004; 16(4):549-61. DOI: 10.1016/j.molcel.2004.11.007. View

11.

Schimmel J, Eifler K, Sigurdsson J, Cuijpers S, Hendriks I, Verlaan-de Vries M . Uncovering SUMOylation dynamics during cell-cycle progression reveals FoxM1 as a key mitotic SUMO target protein. Mol Cell. 2014; 53(6):1053-66. DOI: 10.1016/j.molcel.2014.02.001. View

12.

Enserink J . Sumo and the cellular stress response. Cell Div. 2015; 10:4. PMC: 4476178. DOI: 10.1186/s13008-015-0010-1. View

13.

Kim Y, Nagy K, Keyser S, Schneekloth Jr J . An electrophoretic mobility shift assay identifies a mechanistically unique inhibitor of protein sumoylation. Chem Biol. 2013; 20(4):604-13. PMC: 3711074. DOI: 10.1016/j.chembiol.2013.04.001. View

14.

Li S, Wang J, Hu G, Aman S, Li B, Li Y . SUMOylation of MCL1 protein enhances its stability by regulating the ubiquitin-proteasome pathway. Cell Signal. 2020; 73:109686. DOI: 10.1016/j.cellsig.2020.109686. View

15.

Yates K, Korbel G, Shtutman M, Roninson I, DiMaio D . Repression of the SUMO-specific protease Senp1 induces p53-dependent premature senescence in normal human fibroblasts. Aging Cell. 2008; 7(5):609-21. PMC: 2745089. DOI: 10.1111/j.1474-9726.2008.00411.x. View

16.

Joseph J, Liu S, Jablonski S, Yen T, Dasso M . The RanGAP1-RanBP2 complex is essential for microtubule-kinetochore interactions in vivo. Curr Biol. 2004; 14(7):611-7. DOI: 10.1016/j.cub.2004.03.031. View

17.

Zapata J, Pawlowski K, Haas E, Ware C, Godzik A, Reed J . A diverse family of proteins containing tumor necrosis factor receptor-associated factor domains. J Biol Chem. 2001; 276(26):24242-52. DOI: 10.1074/jbc.M100354200. View

18.

Zhao Q, Ma Y, Li Z, Zhang K, Zheng M, Zhang S . The Function of SUMOylation and Its Role in the Development of Cancer Cells under Stress Conditions: A Systematic Review. Stem Cells Int. 2020; 2020:8835714. PMC: 7683158. DOI: 10.1155/2020/8835714. View

19.

Drabikowski K . Ubiquitin and SUMO Modifications in Stress Response. Curr Issues Mol Biol. 2019; 35:145-158. DOI: 10.21775/cimb.035.145. View

20.

Takemoto M, Kawamura Y, Hirohama M, Yamaguchi Y, Handa H, Saitoh H . Inhibition of protein SUMOylation by davidiin, an ellagitannin from Davidia involucrata. J Antibiot (Tokyo). 2014; 67(4):335-8. DOI: 10.1038/ja.2013.142. View